LONDON, Oct. 12, 2017 /PRNewswire/ --
Heavy Metal Poisoning - Pipeline Review, H2 2017
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare
disease pipeline guide Heavy Metal Poisoning - Pipeline Review, H2
2017, provides an overview of the Heavy Metal Poisoning
(Toxicology) pipeline landscape.
Download the full report:
https://www.reportbuyer.com/product/5142574
Heavy metal poisoning is the accumulation of heavy metals, in toxic
amounts, in the soft tissues of the body. Sources of toxicity can
include environmental, water supply, industrial and hobbies.
Symptoms include headaches, drowsiness, confusion, seizures,
nausea, vomiting, abdominal cramps, tinnitus, goiter, anorexia and
diarrhea. Treatment includes chelation therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest
pipeline guide Heavy Metal Poisoning - Pipeline Review, H2 2017,
provides comprehensive information on the therapeutics under
development for Heavy Metal Poisoning (Toxicology), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide
covers the descriptive pharmacological action of the therapeutics,
its complete research and development history and latest news and
press releases.
The Heavy Metal Poisoning (Toxicology) pipeline guide also reviews
of key players involved in therapeutic development for Heavy Metal
Poisoning and features dormant and discontinued projects. The guide
covers therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Phase II,
Phase I and Preclinical stages are 1, 2 and 5 respectively.
Similarly, the Universities portfolio in IND/CTA Filed, Preclinical
and Discovery stages comprises 1, 1 and 1 molecules,
respectively.
Heavy Metal Poisoning (Toxicology) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to
create effective counter strategies to gain competitive advantage.
The guide is built using data and information sourced from Global
Markets Direct's proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings,
investor presentations and featured press releases from
company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the
most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be
removed or altered based on the availability and relevance of
data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic
landscape of Heavy Metal Poisoning (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Heavy Metal
Poisoning (Toxicology) by companies and universities/research
institutes based on information derived from company and
industry-specific sources.
- The pipeline guide covers pipeline products based on several
stages of development ranging from pre-registration till discovery
and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
- The pipeline guide reviews key companies involved in Heavy Metal
Poisoning (Toxicology) therapeutics and enlists all their major and
minor projects.
- The pipeline guide evaluates Heavy Metal Poisoning (Toxicology)
therapeutics based on mechanism of action (MoA), drug target, route
of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued
pipeline projects.
- The pipeline guide reviews latest news related to pipeline
therapeutics for Heavy Metal Poisoning (Toxicology)
Reasons to buy
- Procure strategically important competitor information, analysis,
and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product
portfolio and create effective counter-strategies to gain
competitive advantage.
- Find and recognize significant and varied types of therapeutics
under development for Heavy Metal Poisoning (Toxicology).
- Classify potential new clients or partners in the target
demographic.
- Develop tactical initiatives by understanding the focus areas of
leading companies.
- Plan mergers and acquisitions meritoriously by identifying key
players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by
understanding Heavy Metal Poisoning (Toxicology) pipeline depth and
focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued
projects and understand from the know-how what drove them from
pipeline.
Download the full report:
https://www.reportbuyer.com/product/5142574
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that
provides all market research reports from top publishers
https://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
View original
content:http://www.prnewswire.com/news-releases/heavy-metal-poisoning---pipeline-review-h2-2017-300535800.html
SOURCE ReportBuyer